Earlier this year, the Trump administration took major action to lower prescription drug costs for Americans.
In February, the White House launched TrumpRX — a website that offers deeply-discounted prescription medications, including GLP-1 weight loss drugs like Ozempic.
Now, broader economic patterns are reflecting the initiative’s tremendous success.
As proof that the Trump administration’s efforts are working extremely well, prescription drug prices in the U.S. have just recorded the steepest annual drop since 1963.
That’s over 60 years!
The Trump War Room account on X is celebrating the big win for the American people:
🚨 HUGE DROP IN DRUG PRICES!
Prescription drug prices just posted their SHARPEST decline in more than 60 years, thanks to TrumpRx, Most Favored Nation drug pricing, and the Trump administration's relentless push to make treatments affordable for every American. 📉🇺🇸 pic.twitter.com/WwAra3o1rl
— Trump War Room (@TrumpWarRoom) August 13, 2026
According to annual data posted in July, prices for prescription drugs have dropped by roughly 3.1% in the last twelve months.
The Washington Post reported further on the data and causes behind it:
Prescription drug prices recorded the biggest year-over-year drop in more than 60 years in July, a startling reduction experts chalked up to an array of factors, including more generics and discount GLP-1 weight-loss drugs.While overall costs for medical services continued to rise, prices for medicinal drugs fell 2.7 percent over the 12 months ending in July, the largest annual drop on record, according to Bureau of Labor Statistics data released Wednesday. Prescription drugs, part of the medicinal drug category, fell by 3.1 percent, the steepest annual decline since March 1963.The White House took credit for the good news, saying President Donald Trump’s efforts to slash drug prices were working. Some experts said a Biden-era policy that requires Medicare to negotiate prices for some popular prescription drugs is more likely to be driving down costs…President Donald Trump has long pledged to bring down prescription drug prices, and the White House made the case Wednesday that the president’s pricing agreements with drug companies and a new initiative, the direct-to-consumer site TrumpRx, are responsible for the lower prices.
“No president in modern history has been able to drastically reduce prescription drug prices across the board except for President Trump,” White House spokesman Kush Desai said in an email. “This is a direct result of the President’s willingness to push the envelope with bold policies that actually put Americans and America First.”
White House officials pointed particularly to the costs of GLP-1 weight-loss drugs, which Trump calls the “fat drug.” TrumpRx, which launched earlier this year, offers GLP-1 drugs for as low as $150 for a starting dose. And under a Medicare pilot program that the administration launched in July, drugmakers Novo Nordisk and Eli Lilly agreed to charge the government just $245 a month for their products, Wegovy, Zepbound and Foundayo.Monthly prices charged to insurance companies previously had topped $1,000. Trump and the drug companies began negotiating last year and announced the rough outlines of the deals in November.“In a matter of months, we got up and running these discounts in a way that they were meaningful for American patients,” said a White House official, speaking on the condition of anonymity because administration staff are not authorized to speak publicly.But bigger trends in the GLP-1 marketplace were already driving down prices independent of Trump’s negotiations, according to experts on drug pricing. Spotty insurance coverage for Wegovy and Zepbound for weight loss has produced enormous demand for lower consumer prices. And cheaper compounded drugs have posed genuine competition for the brand-name companies, adding even greater downward pressure.
In addition to the sharp annual decline, prescription drug costs have fallen by 6.6% in the last six months.
This directly coincides with the launch of TrumpRX.gov back in February.
See for yourself in this data chart:
Just what the doctor ordered! Prescription drug prices have been sliding meaningfully over the last few months, declining 0.8 percent in July and off 6.6 percent SAAR over the last six months. That's the sharpest six month drop on record. pic.twitter.com/yHPyIhVXk9
— RenMac: Renaissance Macro Research (@RenMacLLC) August 12, 2026
Seeking Alpha broke down what the data says further:
Prescription drug prices are falling at their fastest pace on record, offering another notable sign of easing price pressures within the U.S. healthcare sector.
ADVERTISEMENTThe prescription drug component of the Consumer Price Index declined 0.8% in July, while a chart from Renaissance Macro Research, citing Bureau of Labor Statistics data compiled by Haver Analytics, shows prescription drug prices falling at a 6.6% annualized rate over the six months through July, the sharpest six-month decline in the series.
The drop in prescription drug prices stands out against the broader July inflation picture. The U.S. CPI increased 3.4% year over year in July, slowing from 3.5% in June, while prices rose 0.1% month over month.
Core CPI, which excludes food and energy, increased 0.2% from June and was up 2.5% from a year earlier. Shelter rose 0.1% during the month and accounted for roughly two-thirds of the monthly headline increase.
The prescription drug trend has become increasingly pronounced in recent months. The chart shows six-month annualized price growth spending much of the period from 2000 through the mid-2010s in positive territory, often around 2%-6%, before becoming considerably more volatile in the years that followed.
Past presidents promised to lower drug prices back down to the common-sense rates seen in other countries.
But, none could do it — until President Trump came along.
This chart truly says it all:
FACT: President Trump is the first President to actually LOWER prescription drug prices. pic.twitter.com/k2is5zLmzL
— Rapid Response 47 (@RapidResponse47) August 13, 2026
This is a Guest Post from our friends over at WLTReport. View the original article here.
